Loading…
Loading grant details…
| Funder | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE |
|---|---|
| Recipient Organization | University of California Los Angeles |
| Country | United States |
| Start Date | Jul 25, 2024 |
| End Date | Apr 30, 2028 |
| Duration | 1,375 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10975873 |
PROJECT SUMMARY/ABSTRACT The mammalian heart does not robustly regenerate after myocardial infarction and heals via a fibrotic repair response. Scar tissue is non-contractile, increases the hemodynamic burden on the remaining cardiac muscle and over time adverse cardiac remodeling occurs leading to ventricular dilatation and development of heart
failure. Understanding mechanisms of ventricular remodeling to redirect the cardiac injury response from a fibrotic to a reparative one remains one of the broad therapeutic goals in cardiovascular medicine. We have recently identified extracellular nucleotide metabolism as a novel target for cardiac remodeling after ischemic
cardiac injury. We demonstrated that after cardiac injury, the ectonucleotidase ENPP1 is upregulated and hydrolyzes extracellular ATP into AMP. Increased AMP was converted into adenine and extracellular adenine initiated a pro-inflammatory and pro-apoptotic cascade that caused cell death by disrupting NAD and pyrimidine
biosynthesis in non-myocytes and myocytes. However the mechanisms of adenine generation and transport across the cell membrane, molecular and biochemical mechanisms of downstream effects on NAD and pyrimidine biosynthesis and whether the ENPP1/AMP/Adenine axis can be targeted for therapeutic gain to
attenuate post infarct cardiac remodeling are unknown. In this proposal, we form a multi-disciplinary team comprising experts in cardiac physiology, metabolomics, computational biology, and finally population genetics to investigate the role of adenine metabolism in cardiac remodeling, identify its relevance as a potential
therapeutic target and its association with human cardiomyopathy.
University of California Los Angeles
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant